Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 16/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5702666 | 0.91 | CYP1A1 (0.74) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL21960161 | 0.81 | CYP11B1 (0.73) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL22869164 | 0.80 | CYP1A1 (0.55) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL32663058 | 0.80 | CYP1A1 (0.55) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL12302844 | 0.79 | CYP11B1 (0.65) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL168454 | 0.78 | — | — | |
| SCHEMBL744752 | 0.78 | CYP1A1 (0.61) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL15296276 | 0.78 | CYP11B1 (0.64) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL11947382 | 0.78 | CYP1A1 (0.62) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL12303147 | 0.78 | DYRK1A (0.55) | CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | CYP1A1 971/4885CYP1B1 241/4885CYP11B1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.